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Hepatocellular carcinoma (HCC) is increasingly being detected at an earlier stage, owing to the screening programs and regular
imaging follow-up in high-risk populations. Small HCCs still pose diagnostic challenges on imaging due to decreased sensitivity
and increased frequency of atypical features. Diﬀerentiating early HCC from premalignant or benign nodules is important as
management diﬀers and has implications on both the quality of life and the overall survival for the patients. Gadoxetate acid
(Gd-EOB-DTPA, Primovist, Bayer Schering Pharma) is a relatively new, safe and well-tolerated liver-speciﬁc contrast agent for
magnetic resonance (MR) imaging of the liver that has combined perfusion- and hepatocyte-speciﬁc properties, allowing for
the acquisition of both dynamic and hepatobiliary phase images. Its high biliary uptake and excretion improves lesion detection
and characterization by increasing liver-to-lesion conspicuity in the added hepatobiliary phase imaging. To date, gadoxetate acid-
enhanced MRI has been mostly shown to be superior to unenhanced MRI, computed tomography, and other types of contrast
agents in the detection and characterization of liver lesions. This review article focuses on the evolving role of gadoxetate acid in
the characterization of HCC, diﬀerentiating it from other mimickers of HCC.
1. Brief Overviewof HCC
Hepatocellular carcinoma (HCC) is the ﬁfth most common
malignant neoplasm and the third most common cause
of cancer-related death worldwide [1]. There has been a
reported 41% increase in mortality from HCC over the
last 2 decades [2], and HCC continues to be a major
health concern. Many studies have shown that patients
with early-stage HCC, as deﬁned by the Milan criteria [3],
treated either by resection [4, 5] or transplantation [3],
do signiﬁcantly better than those with advanced disease
[6], with 5-year overall survival rate approximating 40–
70% [6, 7] in such cases. The presence of microvascular
invasion—an independent poor prognostic factor regardless
of treatment—is more probable in larger tumors [8–10].
Thus, the detection and accurate characterization of early
focalliverlesioninnormalorcirrhoticliversiscrucialsothat
appropriate treatment can be instituted [11–13].
2. The EvolutioninMagnetic Resonance
Imaging (MRI) of the Liver
MRI has become an established modality for the assessment
of various types of focal liver lesions [14–18]. Nevertheless,
up to 60% of small malignant nodules, particularly those less
than1cmsizeinthebackgroundofcirrhoticliver,aremissed
at MRI [19]. Continued improvement in the MR sequences
and hardware [20, 21], as well as the advent of liver-speciﬁc
contrast agents [22, 23], which are only available for MRI,
have led to the improved diagnostic performance of MRI.
The broad arsenal of MR sequences and multiphasic post-
contrast imaging provide comprehensive information on the
liver lesion by elucidating diﬀerent signal intensities that
reﬂect the inherent properties of the lesion’s composition,
as well as blood ﬂow dynamics, which gives each lesion type
diﬀerent MR characteristic appearances.2 International Journal of Hepatology
3. Liver-SpeciﬁcContrast Agents for MRI
3.1. An Overview. To increase the sensitivity and speciﬁcity
of MRI in the detection and characterization of focal liver
lesions and overcome some of the existing limitations of
extracellular ﬂuid (ECF) agents, which include suboptimal
diﬀerentiation between benign and malignant liver lesions
due to the contrast agents’ non-speciﬁc nature and nephro-
toxicity (nephrogenic systemic ﬁbrosis) that can result with
use of high doses of gadolinium contrasts [24], liver-speciﬁc
contrast agents emerged. Currently, two major classes of
liver-speciﬁc contrast agents exist: (1) hepatocyte-speciﬁc, or
hepatobiliary,agentsand(2)reticuloendothelialcell-speciﬁc,
or nanoparticulate, agents. They are considered “liver-
speciﬁc” as they all cause signiﬁcant liver signal changes after
intravenous administration, with resultant increased liver-
to-lesion conspicuity. The ﬁrst group of contrast agents, as
the name implies, targets the functioning hepatocytes with
varying degree of contrast uptake into them with subsequent
biliary excretion. This is possible because of the addition of
a lipophilic moiety to the gadolinium chelates [25]. Cur-
rently available contrast agents of this type include gadox-
etate acid (Gd-EOB-DTPA or gadolinium ethoxybenzyl
diethylene-triamine pentaacetic acid, Primovist,E o v i s t 
in the USA, Bayer Schering Pharma, Berlin, Germany)
and gadobenate dimeglumine (Gd-BOPTA, Multihance,
Bracco, SpA, Milan, Italy), both of which are gadolinium-
based. Manganese-based paramagnetic agent, mangafodipir
trisodium (Mn-dipyridoxyl 5’phosphate, Teslascan,G E
Healthcare, Oslo, Norway), was another contrast agent
belonging to this group; however, it has been removed for
useintheUnitedStates[26]andwillnotbefurtherdiscussed
here.
The second group of contrast agents target the Kupﬀer
cells of the reticuloendothelial system, where phagocytosis
of contrast agents occur and, by the eﬀects of iron ions,
liver signal intensity decreases giving rise to a “black” liver
[27], instead of “white” liver seen with hepatocyte-speciﬁc
contrast agents.
3.2. Hepatobiliary Agents
Gadoxetate Acid. Gadoxetate acid is a gadolinium-based,
paramagnetic, liver-speciﬁc MR contrast agent with com-
bined perfusion- and hepatocyte-selective properties that is
primarily developed for imaging of the liver to improve
lesion detection and characterization. It has been found in
preclinical studies to be safe and well tolerated with no major
side eﬀects [25, 28–30].
Several unique properties deserve mention. Upon intra-
venous administration of gadoxetate acid, it rapidly dis-
tributes itself in the vascular-interstitial compartment,
enhancing the blood pool, providing acquisition of dynamic
phase images that allows for lesion characterization based
on perfusion. Approximately 50% of the injected dose of
gadoxetateacidisthenselectivelytakenupbythefunctioning
hepatocytes and subsequently excreted into bile, allowing
for the acquisition of the delayed, hepatocyte-speciﬁc phase
that is optimal at 20min post injection. This phase further
improves diagnostic performance by increasing liver-to-
lesion contrast, where lesions with absent or dysfunctional
hepatocytes appear dark against the background white
liver. Because of such high speciﬁcity for hepatocytes, the
recommended dose of gadolinium is 4-fold less than the ECF
agents [25, 29, 30].
The cellular mechanism underlying this high percentage
of contrast volume uptake can be explained by the enhanced
lipophilic property of gadoxetate acid due to the presence of
EOBmoietythatislinkedtothegadoliniumcomplex.Passive
diﬀusion of contrast agent occurs via transporter molecules,
organic anion transporting polypeptide 1 (OATP1), that
are present on the basolateral membrane of the normal
hepatocytes [31–33].
Following a relatively high hepatocyte uptake, studies
have shown that gadoxetate acid is cleared in equal quantities
via bile (50%) and urine (50%). At molecular level, its
excretion into bile is as a result of another type of transporter
molecule present at the canalicular membrane of the cell
calledmultidrug resistance protein 2 (MRP2)[31–33]. In the
event that one of these elimination pathways is impaired, the
othereliminationpathwaycompensates,accordingtoanimal
studies [34, 35]. This theoretically allows patients with either
renal or liver impairment to safely undergo examination by
gadoxetate acid-enhanced MRI, although to date, there is no
human studies to conﬁrm this.
Gadoxetate acid is also highly water-soluble and thus
is bolus-injectable [29, 30]. Previous non-gadolinium liver-
speciﬁccontrastagentsdidnotallowforasingleexamination
of both the vascular- and the liver-speciﬁc phase to be
performed after a single injection in a reasonable time-
frame. However, gadoxetate acid-enhanced MRI is injected
as a bolus and allows for the acquisition of the delayed
(hepatocyte-speciﬁc) phase at 20 minutes post injection via
the mechanism described above, with a total examination
time possible in 35min.
Thediagnosticperformanceofgadoxetateacid-enhanced
MRI versus other forms of imaging or other contrast agents
for MRI will be discussed in a separate section below.
Gadobenate Dimeglumine. Gadobenate dimeglumine (Gd-
BOPTA; Multihance,B r a c c oS p A ,M i l a n ,I t a l y ) ,l i k e
gadoxetate acid, is a gadolinium-based, dual-acting (with
combinedextracellularandliver-speciﬁcproperties)contrast
agent, that provides two-level information of a suspected
lesion: its vascularity (from the dynamic phase imaging)
and its cellularity (from the hepatobiliary phase imaging). It
has been shown to be safe and well-tolerated in preliminary
studies [36–38].
One of the main diﬀerences between the two contrast
agents (see Table 1) is the degree of hepatocyte uptake. With
gadobenate dimeglumine, only 2–4% (as compared to 50%
of gadoxetate acid) is taken up by functioning hepatocytes;
it is predominantly (96%) cleared by the kidneys [37].
This has several implications: (1) theoretically, the higher
proportion of contrast elimination via the kidneys means
patients with signiﬁcant renal impairment should not beInternational Journal of Hepatology 3
Table 1: Major diﬀerences between gadoxetate acid and gadobenate dimeglumine.
Properties in comparison Gadoxetate acid Gadobenate dimeglumine
% contrast uptake 50% 2–4%
Hepatobiliary phase image acquisition 10–45 minutes postcontrast administration 60–120min postcontrast administration
Duration of liver enhancement 2hrs 4hrs
Clearance 50% biliary excretion, 50% renal excretion 2–4% biliary excretion, 96% renal excretion
Recommended dosage 0.025mmol/kg, bolus injection at 2mL/sec 0.1mmol/kg bodyweight, bolus injection at 2mL/sec
Table 2
Diﬀerences SPIO Hepatobiliary agents
Targeting cells Kupﬀer cells Functioning hepatocytes
Liver parenchyma Black liver White liver
Malignant liver lesion White nodule Black nodule
advised to undergo MR studies with this contrast; (2)
acquisition time of the hepatocyte-speciﬁc phase occurs
later than that of gadoxetate acid (40min versus 20min),
(3) recommended dosage of contrast volume is diﬀerent
(higher with gadobenate dimeglumine) [36–39]. Despite
the diﬀerences in the degree of hepatocyte uptake and the
time course of liver enhancement, it has been found that
both agents, during their maximum enhancement, provide
comparable enhancement of the liver parenchyma [40]. For
gadobenate dimeglumine, this is achieved because OATP
phosphorylation—occurs when the agent is taken up into
the hepatocytes—causes changes in MRP2 location and
expression, preventing the exit of contrast material into bile
[41, 42].
Several studies have demonstrated superior diagnostic
performance of gadobenate dimeglumine-enhanced MRI in
the detection and characterization of benign and malignant
liver nodules over non-speciﬁc extracellular agents and
ferumoxides [43–48]. In the detection of HCC, Choi et
al. [49] reported a sensitivity of 80–85% and a positive
predictive value of 65-66%.
3.3. Reticuloendothelial Cell-Speciﬁc Agents. Superparamag-
netic iron oxide (SPIO) is another class of liver-speciﬁc
contrast agents for MR imaging of the liver. Ferucarbotran
(Resovist; Bayer Schering, Berlin, Germany), a commonly
used SPIO, works by targeting the Kupﬀer cells of the
reticuloendothelial system (RES), which are present in
various organs, including the liver, spleen, and bone marrow
[50]. It is also administered intravenously as a bolus [51].
Unlike gadoxetate acid that can evaluate a liver lesion by
its function and vascularity, SPIO can only evaluate a lesion
functionally.
Generally, malignant lesions (HCC) are presumed to
lack phagocytic activity and thus appear hyperintense with
respect to the hypointense liver parenchyma on SPIO-
enhanced MRI [27, 52]. This diﬀers from ﬁndings of
hepatocyte-speciﬁc contrast-enhanced MRI, where most
HCC nodules appear hypointense with respect to the
hyperintense liver parenchyma in the hepatobiliary phase.
However, it is important to note that up to 60% of well-
diﬀerentiated HCCs are not hyperintense on ferucarbotran-
enhanced MRI possibly due to the fact that early HCCs may
retain normal Kupﬀer cell function and counts [53–55].
Table 2 summarizes the major diﬀerences between the
two types of liver-speciﬁc contrast agents.
4. GadoxetateAcid for Detection and
Characterization of HCC
The liver parenchyma enhances strongly in the hepatocyte
phase on T1-weighted images, starting at 10–20min after the
intravenousinjectionofcontrast.Thisformsthebackground
against which various types of nodules, which do or do not
contain functioning hepatocytes, stand out. Nodules that
do not contain normal functioning hepatocytes, such as
most HCC or liver metastases, lack contrast uptake and are
usually depicted as low-intensity (hypointense) lesions. On
the other hand, nodules that do contain (varying degrees
of) functioning hepatocytes, such as regenerative nodules of
focal nodular hyperplasia (FNH), appear enhanced, either
to a similar or higher degree to the surrounding liver
parenchyma.
HCC. Using AASLD criteria [56], HCC can be diagnosed
noninvaively in at-risk patients with contrast-enhanced
imaging, typically showing arterial phase enhancement and
venous or delayed phase washout on CT or MRI [57, 58].
The presence of fat or late enhancing pseudocapsule are sup-
portive features. Complementary features on MRI include
mild-moderate hyperintensity on T2-weighted images and
restricted diﬀusion on diﬀusion-weighted imaging (DWI)
sequences. With the recent international consensus recogni-
tion of the early HCC nodule as a pathologic entity, their
imaging correlates are also being increasingly recognized
at hepatobiliary phase imaging as the decreased expression
of anion transporters may predate the development of
overt hypervascularity. At conventional dynamic contrast-
enhanced imaging, a signiﬁcant proportion of these early
HCCs will not show typical diagnostic arterial phase
hyperenhancement and would be potentially misdiagnosed
as benign lesions, such as regenerative or dysplastic nod-
ules. At hepatobiliary phase imaging post gadoxetate acid
administration, 3 patterns of HCC have been described,
depending on whether they express transporter molecules
OATP1 [31] on their membranes: (1) typically, as arterial
hypervascularized lesion and washout on a 3-min late phase
MRI and hypointense lesion at 10–20-min hepatocyte phase4 International Journal of Hepatology
(a) (b) (c)
Figure 1: (a) Gadoxetate acid-enhanced MRI in the arterial phase in a 51-year-old male with alcoholic liver cirrhosis showing a
hyperenhancing nodule in the liver segment 6. (b) Equilibrium phase imaging shows isointense appearance with no hypointense washout.
The diagnosis of HCC is therefore not conﬁrmed in the dynamic vascular phases. (c) Hepatobiliary phase imaging at 20 minutes after
injection shows a hypointense nodule against the background of enhancing liver parenchyma, implying lack of lesional uptake. This
additional information allowed more conﬁdent diagnosis of HCC. Final histopathology was a well-diﬀerentiated Edmondson-Steiner grade
I HCC.
because most HCCs do not contain functioning hepatocytes
and hence >80% of HCCs appear hypointense in relation to
the surrounding enhanced liver parenchyma [59, 60]; (2) as
isointense or hyperintense lesions at 10–20-min hepatocyte
phase because some moderate or well-diﬀerentiated HCCs
may overexpress anion transporters OATP1 resulting in
uptake of contrast agent in 10–20% of cases [59, 60]; (3)
occasionally in approximately 10% of HCCs especially small
lesions may present as hypointense lesions on hepatocyte
phase imaging without accompanying arterial hypervascu-
larization or T2-weighted or DWI hyperintensity [61].
The following underlying cellular mechanism explains
the above phenomena. In a normal liver, after intravenous
administration, gadoxetate acid ﬁrst reaches the extracel-
lular space (the vasculature). It then enters the normal
functioning hepatocytes via transporter molecule organic
anion transporting peptides (OATPs) that are located in the
hepatocyte’s basolateral membrane. The contrast agents then
exits the hepatocytes into bile (in 50% of injected contrast
volume) through another transporter molecule located on
the canalicular membrane, the multidrug resistance protein
2( M R P 2 )[ 31–33]. In cirrhotics, these two transporter
molecule expressions undergo modiﬁcations. It has been
establishedthatthepresenceofOATPsdeterminestheuptake
of gadoxetate acid in hepatocellular carcinoma [62]. In 2010,
Tsuboyama et al. [63] found that when OATPs are present
in HCC, the expression and location of MRP2 is the one
ultimately responsible for the cellular accumulation or lack
of it. If the MRP2 are present on the normal canalicular
membrane, the contrast material will exit into bile and
that HCC nodule will appear hypointense. Correspondingly,
Tsuda and Matsui [64] found that the presence of liver
cirrhosisupregulatesMRP2,whichpromotestheelimination
of gadoxetate acid. Thus, although some HCCs may contain
OATPs, most still appear hypointense relative to the liver
enhancement. On the contrary, if MRP2 is situated in the
pseudoglands, the contrast agent will not be able to exit
into bile, and its accumulation in the HCC lesion causes
it to appear hyperintense [63]. A similar report regarding
aboveﬁndingswithuseofgadobenatedimegluminehasbeen
described by Planchamp C and team in his animal study
[41, 42].
Figures 1(a)–1(c) illustrate the features of a typical
HCC on gadoxetate acid-enhanced MRI. Figures 2(a)–2(d)
demonstrate how gadoxetate acid-enhanced MRI can assist
in the characterization of a non-speciﬁc, non-enhancing
lesion on triphasic CT scan. Figures 3(a)–3(f) demonstrate
another HCC with hepatobiliary excretion on gadoxetate
acid-enhanced MRI.
4.1. Diﬀerentiating HCC from Regenerative or Dysplastic
Nodules. Regenerative or dysplastic nodules are theoretically
not malignant and hence may be expected to exhibit
normal expression of the uptake transporter OATP1 and
the excretory transporter MRP2. They take up contrast
material and appear enhanced unlike most HCC [65]. Kudo
reported that the diﬀerentiation of HCC from premalignant
lesion can be achieved with 93% accuracy when investigated
with gadoxetate acid-enhanced MRI [66]. However, as
hepatocarcinogenesis is a stepwise continuum, a variable
proportion of high-grade dysplastic nodules will begin to
show lack of uptake of gadoxetate acid, resulting in overlap
with early HCCs [67]. This highlights the potential pitfall
in these borderline category cases. Currently, the Japan
Liver Oncology Group (JLOG) is conducting a clinical
trial to address this issue, to determine the frequency of
dysplastic lesions appearing as hypointense, isointense, or
hyperintenselesioninthehepatocytephase[68].Preliminary
data from an Italian study suggests that a proportion of
hypointense nodules on hepatocyte phase are high-grade
dysplastic nodules and not always speciﬁc for HCCs [67].
From a practical standpoint, it may be appropriate to followInternational Journal of Hepatology 5
(a) (b)
(c) (d)
Figure 2:(a–c)Contrast-enhancedCTinthearterial,venousandequilibriumphasesofa75-year-oldmaleHepatitisBviruscarriershowing
anindeterminateslightlyhypodensenonhypervascularnoduleintheliversegment6.(d)Gadoxetateacid-enhancedMRIinthehepatobiliary
phase 20 minutes after injection showing a hypointense nodule against the background of enhancing liver parenchyma, implying lack of
lesional uptake, suspicious for HCC or high-grade dysplastic nodule. Final surgical histopathology was a well-diﬀerentiated Edmondson-
Steiner grade I HCC.
up these diﬃcult nodules with interval imaging if they are
smaller than 1.5cm, whilst a more proactive approach such
as biopsy may be advocated if lesions are larger than 1.5cm
since larger lesions tend to have a higher risk of malignancy
or show microvascular invasion [69, 70].
4.2. Diﬀerentiating HCC from Hypervascular/Arterial
Enhancing Pseudolesions. Arterioportal shunts are also
one of the main mimickers of hypervascular HCCs on
conventional dynamic contrast-enhanced CT and MRI
[71, 72]. These are relatively of higher prevalence in the
cirrhotic liver and appear as ﬂash-enhancing lesions ranging
from 5 to 20mm and are typically not visible on other
phases or sequences. However, as up to 50% of all ﬂash-
enhancing foci are eventually found to be HCCs, conﬁdent
diagnosis at a single time-point is diﬃcult without the
beneﬁt of serial followup. However, Motosugi and Sun
et al. recently reported that gadoxetate acid-enhanced
hepatocyte-phase MR images and diﬀusion weighted images
are useful for distinguishing hypervascular pseudolesions
from hypervascular HCCs [72, 73].
4.3. Diﬀerentiating HCC from Focal Nodular Hyperplasia
(FNH). Although regarded as the second most common
benign tumor of the liver, FNH is less of a consideration
in the cirrhotic liver. Nonetheless, they can be conﬁdently
distinguished from adenomas/metastases on gadoxetate
acid-enhanced MRI as they typically appear as isointense
or hyperintense on hepatocyte-phase images due to the
presence of functioning hepatocytes and the presence of
biliary canaliculi. Accurate characterization of FNH has been
reported as high as 88% [74, 75]. Unnecessary biopsies,6 International Journal of Hepatology
(a) (b) (c) (d)
(e) (f)
(g)
Figure 3: (a–d) Gadoxetate acid-enhanced MRI in the precontrast, arterial, venous, and equilibrium phases of Hepatitis B virus carrier
showinganoduleinsegment6oftheliverwithearlyarterialenhancementandlate-phasewashoutcompatiblewithHCC.(e),(f)Gadoxetate
acid-enhanced MRI in the hepatobiliary phase 10–20 minutes after injection, showing progressively hyperintense portions of the nodule,
implying lesional uptake, in a heterogeneous pattern. Note the hypointense pseudocapsule. Final surgical histopathology showed moderately
diﬀerentiated Edmondson-Steiner grade II HCC. (g) Coronal view.
operations or close monitoring with 3–6 monthly MR or
ultrasound imaging can be avoided.
Figures 4(a)–4(f) demonstrate typical FNH features on
gadoxetate acid-enhanced MRI.
4.4. Diﬀerentiating HCC from Liver Adenoma. Hepatic ade-
noma is a rare, benign liver tumor that predominantly
aﬀects women who take oral contraceptive pills. Like FNH,
adenomas are typically hypervascular during the arterial
phase but there is no central scar. In the hepatobiliary phase,
it is thought that adenomas do not typically accumulate
gadoxetate acid due to absence of functioning biliary ele-
ments unlike FNH. However, a few cases with hyperintense
appearance in the hepatobiliary phase have been reported
[76–78]. Currently, there is little published data to conﬁrm
the predominant pattern for adenomas, and larger studies
with histopathological conﬁrmation are needed.International Journal of Hepatology 7
(a) (b)
(c) (d)
(e) (f)
Figure 4: (a–d) Gadoxetate acid-enhanced MRI in the precontrast, arterial, venous, and equilibrium phases of 37-year-old female non-
Hepatitis B or C virus carrier showing a large mass in the right lobe of the liver with early arterial enhancement and persistent late-phase
enhancement with a small central hypointense scar. (e, f) Gadoxetate acid-enhanced MRI in the hepatobiliary phase 10–20 minutes after
injection showing progressively hyperintense enhancement, in a homogeneous pattern apart from the hypointense small central scar. The
MRI ﬁndings are typical for focal nodular hyperplasia.
5.GadoxetateAcid: Sensitivity,Speciﬁcity,and
AccuracyinHCC DetectioninComparison
with Other Types of Contrast Agents or
ImagingTechniques
Earlier studies comparing the diagnostic performance of
gadoxetate acid-enhanced MRI against unenhanced MRI
[75, 79, 80] and biphasic spiral CT [81, 82] showed clear
superiority of gadoxetate acid-enhanced MRI over the other
two in the detection and characterization of focal liver
lesions, with as high as 10% increase in sensitivity [75,
79, 80] as compared to the unenhanced scan and 20%
increase in sensitivity and 9% increase in speciﬁcity when
comparedtobiphasicCT[81,82].Thisincreaseindiagnostic
performance is notably signiﬁcant for lesions smaller than
1cm. At present, multidetector CT (MDCT) has surpassed
spiral CT as the imaging of choice for the evaluation of focal
liver lesion.8 International Journal of Hepatology
5.1. Evaluation against MDCT. In 2009, Kim et al. [59]
reported his results on the diagnostic performance of
gadoxetic acid-enhanced MRI and MDCT on the detection
of HCC. His study population comprised of 83 HCCs
(75 moderately-diﬀerentiated HCCs, 5 well-diﬀerentiated
HCCs, 3 poorly-diﬀerentiated HCCs) with a mean size of
2.9cm. Forty-eight percent of this population had Child-
Pugh A cirrhosis; the rest had chronic hepatitis. The group
found that although there is a trend for gadoxetate acid-
enhanced MRI to have better performance in the detection
of HCC, especially for those smaller or equal to 1cm in
size, there is otherwise no statistical signiﬁcance in the
performance of the two. The sensitivity was 91.6–94% in
the gadoxetate group versus 82.2%–92.8% in the MDCT
group. It is important to keep in mind that this study
comprised mostly larger-sized tumors that are moderately-
diﬀerentiated on the background of good liver function.
In the same year, another Korean group [83] published
a statistically superior diagnostic accuracy result of HCC
detection with gadoxetate acid-enhanced MRI when com-
pared to MDCT. Here, 81 HCCs with a mean size of 1.5cm
were analysed by 2 observers. The group reported 91.4%
sensitivity in the gadoxetate group versus 71.6% sensitivity
in the MDCT group, with 24.7% higher percentage of HCC
detection in smaller lesions (<1.5cm). No nodules were
missed at MRI but 4/81 nodules that were seen on MDCT
were not veriﬁable on gadoxetate acid-enhanced MRI. It is
important to note that more than 50% of the population had
cirrhosis but not all had histological conﬁrmation.
Finally, in 2010, Martino et al. [84] also found that
gadoxetate acid-enhanced MRI yielded superior diagnostic
performance in HCC detection in the 87 HCCs (mean size
1.8cm) on the background of liver cirrhosis, in both the
diagnostic accuracy and sensitivity, when compared with
those analysed by MDCT. Diagnostic accuracy was 88%
and 74% and average sensitivity was 85% and 69% for the
gadoxetate group and the MDCT group, respectively. This
increasedperformanceisclearforlesionssmallerthan1.5cm
as well. However, it must be noted that only 61% of the
population had histological diagnosis.
5.2. Evaluation against Other Contrast Agents
5.2.1. Comparing Gadoxetate Acid-Enhanced MRI and
Gadobenate Dimeglumine-Enhanced MRI in the Detection
and Characterization of HCC. Although prior study showed
that both gadoxetate acid and gadobenate dimeglumine can
achieve similar enhancement in normal liver, this ﬁnding
is diﬀerent in the cirrhotic liver. Filippone [85] found, in
his multicenter trial comprising of 70/295 patients with
cirrhotic livers, that use of gadoxetate acid resulted in better
liver enhancement in the overall (57.24% versus 32.77%)
and in the cirrhotic subgroup (57.00% versus 26.85%)
population than when gadobenate dimeglumine is used. The
enhancement pattern of liver parenchyma for the cirrhotics
ongadoxetateacid-enhancedMRI,however,wascomparable
totheenhancementabilityachievedintheoverallpopulation
using gadoxetate acid (57.00% versus 57.24%).
Based on these above ﬁndings, one would think that
this means deﬁnite improvement in HCC detection in
gadoxetate acid-enhanced MRI compared to gadobenate
dimeglumine-enhanced MRI in the detection of HCCs in
the cirrhotic subgroup because of presumed increase in
liver-to-lesion contrast. However, Park et al. [86]—who, to
the authors’ best knowledge, is the only group that com-
pared the diagnostic performance of gadoxetate acid- and
gadobenate dimeglumine-enhanced MRI for the detection
of hepatocellular carcinoma—reported similar diagnostic
performance of gadoxetic acid- and gadobenate-enhanced
MRI. It is important to note here that the study population
is small (18 patients with 22 HCCs), with a relatively large-
sized HCCs (mean size of 2.9cm) and in patients with good
liver function. Overall, the authors still advocate the use of
gadoxetate acid due to the other additional beneﬁts of earlier
enhancement and shorter total examination time.
5.2.2. Comparing Gadoxetate Acid-Enhanced MRI and SPIO-
Enhanced MRI in the Detection and Characterization of HCC.
SPIO has been used and proven eﬀective in the detection of
malignant focal liver lesions, both HCC and metastases [87,
88], with a sensitivity range of 68%–97% [89, 90].
Kimetal.[91]reportedsigniﬁcantlyimprovedsensitivity
(90.7% versus 84.7%) in the detection of 118 histologically
conﬁrmed HCCs by gadoxetate acid-enhanced MRI when
compared with SPIO-enhanced study. The authors noticed
that the improved sensitivity is most pronounced for lesions
greater than 1.5cm in size and that lesion characterization
with certainty remains an issue with gadoxetate acid-
enhanced MRI, despite its superior detection rate.
Lee et al. [92] reported similar diagnostic performance
between gadoxetate acid- and ferucarbotran-enhanced MRI
on a 3.0-T unit in a population of 38 histologically proven
HCCs. However, it should be noted that the majority of
the HCCs in the study were of relatively larger size (mean
size of tumors is 2.8cm), and 34/38 HCCs were moderately
diﬀerentiated HCCs.
Okada et al. [93] set out to compare the diagnostic
performance between the two types of contrast-enhanced
MRI in characterizing enhancement patterns of well-
diﬀerentiated HCC and dysplastic nodules. They can have
similar MRI features, making accurate radiological diagnosis
diﬃcult. His study population of HCCs was diﬀerent from
the study by Lee. In this prospective study analyzing 37
histologically proven HCC in 36 patients: 22/37 were well-
diﬀerentiated HCCs with a mean size of 14mm (sizes
ranging from 6 to 28mm; 15/37 were moderate to poorly-
diﬀerentiated HCCs (as compared to the study by Lee JY
where 35/38 were moderately-diﬀerentiated HCCs) with
sizesrangingfrom13–46mm;4weredysplasticnoduleswith
a mean of 16mm (sizes ranging from 13 to 22mm). Okada
found gadoxetate acid-enhanced MRI to be more sensitive
thanferucarbotran-enhancedMRIintheaccurateevaluation
of the enhancement patterns of his study population.
However, one must note that 74% of patients in the study
were Child-Pugh class A; Child-Pugh class C were excluded
from the study.
6. Accepted Gadoxetate Acid-Enhanced
MR Protocol
Thecurrentsuggestedprotocolforgadoxetateacid-enhanced
MRimagingofthelivercomprisestwomainparts,aslaidoutInternational Journal of Hepatology 9
below[69,76].Inordertoreducethetimethepatientspends
in the MRI room, the longer T2-weighted and diﬀusion-
weighted sequences can be performed after the dynamic
post-contrast phase, rather than prior to the injection of
contrast as in conventional MRI protocols, without signif-
icant alteration of the lesional signal characteristics. The
total scan time is slightly longer than conventional MR but
the diﬀerence is minimized by this rearrangement of the
sequences.
(1) Precontrastsequences(similartothatofconventional
MR imaging) includes the following.
(a) Coronal single shot, fast spin echo T2-weighted
sequences.
(b) T1-weighted in/opposed phase. This combi-
nation sequence allows comparison of the
varying signal intensities of the same lesion,
further deﬁning its true nature. This sequence
is most helpful in the interpretation of fat-
containing tissues or lesions, for example, in
the determination of hepatic steatosis. Fatty
lesions demonstrate “signal drop”—where fat,
which is bright during the ‘in’ phase, appears
correspondingly darkerin the“opposed” phase.
(c) T1-precontrast sequence. This forms the base-
line signal to which post-contrast images are
compared to.
(2) Administration of gadoxetate acid, either as a stan-
dard dose of 10mls or 0.025mmol/kg body weight of
gadoxetate acid, given as an intravenous bolus at 1.5–
2ml/sec, ﬂushed immediately with 20mL saline.
(3) Post-contrast sequences are then obtained in the
following manner.
(a) Dynamic imaging.
(i) T1-weighted dynamic images are to
be obtained immediately post-contrast
administration. This includes the arterial,
porto-venous, and equilibrium phase up
to 5 minutes post-contrast images. These
images evaluate a lesion’s perfusion and
washout characteristics.
(b) Axial T2-weighted and diﬀusion-weighted
sequences.
(c) Hepatobiliary phase.
(i) T1-weighted hepatobiliary phase in both
axial and coronal views. These images are
usually acquired at 10–20 minutes post
contrast administration. This hepatobil-
iary phase utilizes the unique properties
of gadoxetate acid, as discussed earlier, to
yield additional valuable information for
lesion characterization.
7. Area of FutureStudies
Most HCCs arise in the background of cirrhosis. Most of
these early small nodules (<2cm) in the background of early
liver cirrhosis have been shown to appear hypointense rela-
tive to the surrounding liver parenchyma on the hepatocyte-
speciﬁc phase of gadoxetate acid-enhanced MRI [60, 61,
94–98], although the signal enhancement of cirrhotic liver
parenchyma is not as strong as that of normal liver [69, 80].
However, challenges remain in three categories of patients:
(1) those that have small lesions in the background of
early liver cirrhosis—distinguishing the small HCCs from
other premalignant nodules is diﬃcult radiologically; (2)
those with renal impairment—can gadoxetate acid be safely
used in this group of patients?; (3) those with advanced or
decompensated liver cirrhosis—suboptimal or no enhanced
liver-to-lesion contrast can be achieved.
Cruite et al. [65] discussed the reasons behind the
3 unique diagnostic challenges faced in the diagnoses of
HCCsinpatientswithadvancedordecompensatedcirrhosis.
Firstly, there is expected impairment of contrast agent
uptake due either to the reduced number of functional or
the presence of dysfunctional hepatocytes. Secondly, there
may be delayed or decreased biliary excretion from the
impaired contrast uptake. Correspondingly, enhancement of
the liver parenchyma, and the liver-to-lesion conspicuity, is
decreased. In addition, there may also be pooling of contrast
agent in the blood because of the signiﬁcant reduction in
the hepatic, and possibly renal, elimination as patients with
advanced liver disease often have renal impairment as well,
making gadoxetate acid behave like an ECF agent. Further
studies are required to conﬁrm the role of gadoxetate acid-
enhancedMRIinthediagnosisofliverlesionsinthesegroups
of patients.
8. Summary
Gadoxetate acid-enhanced MRI of the liver has certain
advantages over other imaging modalities in the detection
and characterization of HCC in the high-risk liver. With
increasing experience and application globally, it may poten-
tially be established as the diagnostic imaging modality of
choice in this setting.
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